Platelet release in coronary heart disease: Effect of antiplatelet drugs and coronary artery bypass graft

Hamid Al-Mondhiry, William S. Pierce, John L. Pennock

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We report serial measurements of in vivo platelet release products β-thromboglobulin and platelet factor 4 in 38 patients with coronary artery disease who underwent coronary artery bypass graft surgery. All patients were given dipyridamole preoperatively and both dipyridamole and aspirin postoperatively. Assays of plasma β-thromboglobulin and platelet factor 4 were performed immediately before surgery, at discharge, and at follow-up visits. At initial evaluation, 22 patients with prior myocardial infarction had significantly elevated plasma β-thromboglobulin levels (p = 0.0004). In the preoperative period, the use of dipyridamole caused some reduction of plasma β-thromboglobulin and platelet factor 4, but the difference was not statistically significant. Six to 12 days after surgery, all patients had plasma β-thromboglobulin concentrations higher than the preoperative levels despite the continued ingestion of dipyridamole and aspirin. At a follow-up visit, 30 to 133 days after surgery, only patients with previous myocardial infarction had β-thromboglobulin levels higher than their preoperative values. However, compared with controls, all patients who underwent coronary artery bypass graft surgery had elevated plasma levels of β-thromboglobulin in both the early and late postoperative periods. In this group of patients, successful revascularization of the myocardium, as indicated by relief of symptoms, did not completely inhibit platelet activation.

Original languageEnglish (US)
Pages (from-to)397-402
Number of pages6
JournalThe Journal of Laboratory and Clinical Medicine
Volume105
Issue number3
StatePublished - Jan 1 1985

Fingerprint

Platelet Aggregation Inhibitors
Platelets
Grafts
Coronary Artery Bypass
Dipyridamole
Surgery
Coronary Disease
Platelet Factor 4
Blood Platelets
Transplants
Plasmas
Aspirin
Ambulatory Surgical Procedures
Myocardial Infarction
Preoperative Period
Assays
Platelet Activation
Chemical activation
Postoperative Period
Coronary Artery Disease

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Al-Mondhiry, Hamid ; Pierce, William S. ; Pennock, John L. / Platelet release in coronary heart disease : Effect of antiplatelet drugs and coronary artery bypass graft. In: The Journal of Laboratory and Clinical Medicine. 1985 ; Vol. 105, No. 3. pp. 397-402.
@article{9c7a875d244a4804be27d88ef5817cca,
title = "Platelet release in coronary heart disease: Effect of antiplatelet drugs and coronary artery bypass graft",
abstract = "We report serial measurements of in vivo platelet release products β-thromboglobulin and platelet factor 4 in 38 patients with coronary artery disease who underwent coronary artery bypass graft surgery. All patients were given dipyridamole preoperatively and both dipyridamole and aspirin postoperatively. Assays of plasma β-thromboglobulin and platelet factor 4 were performed immediately before surgery, at discharge, and at follow-up visits. At initial evaluation, 22 patients with prior myocardial infarction had significantly elevated plasma β-thromboglobulin levels (p = 0.0004). In the preoperative period, the use of dipyridamole caused some reduction of plasma β-thromboglobulin and platelet factor 4, but the difference was not statistically significant. Six to 12 days after surgery, all patients had plasma β-thromboglobulin concentrations higher than the preoperative levels despite the continued ingestion of dipyridamole and aspirin. At a follow-up visit, 30 to 133 days after surgery, only patients with previous myocardial infarction had β-thromboglobulin levels higher than their preoperative values. However, compared with controls, all patients who underwent coronary artery bypass graft surgery had elevated plasma levels of β-thromboglobulin in both the early and late postoperative periods. In this group of patients, successful revascularization of the myocardium, as indicated by relief of symptoms, did not completely inhibit platelet activation.",
author = "Hamid Al-Mondhiry and Pierce, {William S.} and Pennock, {John L.}",
year = "1985",
month = "1",
day = "1",
language = "English (US)",
volume = "105",
pages = "397--402",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "3",

}

Platelet release in coronary heart disease : Effect of antiplatelet drugs and coronary artery bypass graft. / Al-Mondhiry, Hamid; Pierce, William S.; Pennock, John L.

In: The Journal of Laboratory and Clinical Medicine, Vol. 105, No. 3, 01.01.1985, p. 397-402.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Platelet release in coronary heart disease

T2 - Effect of antiplatelet drugs and coronary artery bypass graft

AU - Al-Mondhiry, Hamid

AU - Pierce, William S.

AU - Pennock, John L.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - We report serial measurements of in vivo platelet release products β-thromboglobulin and platelet factor 4 in 38 patients with coronary artery disease who underwent coronary artery bypass graft surgery. All patients were given dipyridamole preoperatively and both dipyridamole and aspirin postoperatively. Assays of plasma β-thromboglobulin and platelet factor 4 were performed immediately before surgery, at discharge, and at follow-up visits. At initial evaluation, 22 patients with prior myocardial infarction had significantly elevated plasma β-thromboglobulin levels (p = 0.0004). In the preoperative period, the use of dipyridamole caused some reduction of plasma β-thromboglobulin and platelet factor 4, but the difference was not statistically significant. Six to 12 days after surgery, all patients had plasma β-thromboglobulin concentrations higher than the preoperative levels despite the continued ingestion of dipyridamole and aspirin. At a follow-up visit, 30 to 133 days after surgery, only patients with previous myocardial infarction had β-thromboglobulin levels higher than their preoperative values. However, compared with controls, all patients who underwent coronary artery bypass graft surgery had elevated plasma levels of β-thromboglobulin in both the early and late postoperative periods. In this group of patients, successful revascularization of the myocardium, as indicated by relief of symptoms, did not completely inhibit platelet activation.

AB - We report serial measurements of in vivo platelet release products β-thromboglobulin and platelet factor 4 in 38 patients with coronary artery disease who underwent coronary artery bypass graft surgery. All patients were given dipyridamole preoperatively and both dipyridamole and aspirin postoperatively. Assays of plasma β-thromboglobulin and platelet factor 4 were performed immediately before surgery, at discharge, and at follow-up visits. At initial evaluation, 22 patients with prior myocardial infarction had significantly elevated plasma β-thromboglobulin levels (p = 0.0004). In the preoperative period, the use of dipyridamole caused some reduction of plasma β-thromboglobulin and platelet factor 4, but the difference was not statistically significant. Six to 12 days after surgery, all patients had plasma β-thromboglobulin concentrations higher than the preoperative levels despite the continued ingestion of dipyridamole and aspirin. At a follow-up visit, 30 to 133 days after surgery, only patients with previous myocardial infarction had β-thromboglobulin levels higher than their preoperative values. However, compared with controls, all patients who underwent coronary artery bypass graft surgery had elevated plasma levels of β-thromboglobulin in both the early and late postoperative periods. In this group of patients, successful revascularization of the myocardium, as indicated by relief of symptoms, did not completely inhibit platelet activation.

UR - http://www.scopus.com/inward/record.url?scp=0022343698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022343698&partnerID=8YFLogxK

M3 - Article

C2 - 2579177

AN - SCOPUS:0022343698

VL - 105

SP - 397

EP - 402

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 3

ER -